首页> 美国卫生研究院文献>Clinical Cardiology >Electrical Plasticity and Cardioprotection in Myocardial Ischemia—Role of Selective Sodium Channel Blockers
【2h】

Electrical Plasticity and Cardioprotection in Myocardial Ischemia—Role of Selective Sodium Channel Blockers

机译:心肌缺血中的电可塑性和心脏保护作用-选择性钠通道阻滞剂的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The concept of electrical protection of the ischemic myocardium is in constant evolution and has recently been supported by experimental and clinical studies. Historically, antiplatelet agents, angiotensin‐converting enzyme inhibitors, β‐blockers, and statins have been all proposed as drugs conferring anti‐ischemic cardioprotection. This was supported by the evidence consistently indicating that all these drugs were capable of reducing mortality and the risk of repeat myocardial infarction. The electrical plasticity paradigm is, however, a novel concept that depicts the benefits of improved sodium channel blockade with drugs such as ranolazine and cariporide. Although it has been hypothesized that the protective role of ranolazine depends on decreased fatty acid β‐oxidation affecting preconditioning, we speculate against such a hypothesis, because inhibition of β‐oxidation requires higher concentrations of the drug, above the therapeutic range. Rather, we discuss the key role of calcium overload reduction through inhibition of the late sodium current (INa). Mechanisms driving cardioprotection involve the block of a cascade of complex ionic exchanges that can result in intracellular acidosis, excess cytosolic calcium, myocardial cellular dysfunction, and eventually cell injury and death. In this review we discuss the studies that demonstrate how electrical plasticity through sodium channel blockers can promote cardioprotection against ischemia in coronary heart disease.
机译:缺血性心肌的电保护概念在不断发展,最近已得到实验和临床研究的支持。从历史上看,抗血小板药物,血管紧张素转换酶抑制剂,β受体阻滞剂和他汀类药物都被认为是具有抗缺血性心脏保护作用的药物。一直有证据表明所有这些药物都能够降低死亡率和再次发生心肌梗塞的风险,这证明了这一点。但是,电可塑性范式是一个新颖的概念,它描述了使用雷诺嗪和卡立哌利德等药物改善钠通道阻滞的好处。尽管已经假设雷诺嗪的保护作用取决于降低的脂肪酸β-氧化作用,从而影响预处理,但我们推测这种假设是对的,因为抑制β-氧化作用需要更高的药物浓度,超过治疗范围。相反,我们讨论了通过抑制晚期钠电流(INa)来减少钙超载的关键作用。驱动心脏保护的机制涉及一系列复杂的离子交换,这些离子交换可导致细胞内酸中毒,胞质钙过多,心肌细胞功能障碍,最终导致细胞损伤和死亡。在这篇综述中,我们讨论了研究,这些研究证明了通过钠通道阻滞剂的电可塑性如何能够促进针对冠心病局部缺血的心脏保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号